THE ULTIMATE PEPTIDE PROTOCOL BIBLE
⚠ For research use only. Not for human use. Not medical advice.
Metabolic

Cagrilintide + Semaglutide Blend

Quick summary

A blend of an amylin analog and a GLP-1 receptor agonist. Research focus: amylin + GLP-1 co-signaling. This page leads with SRP's low-and-slow starting dose.

View product: Cagrilintide + Semaglutide 5mg + 5mg Blend →
Dosing frequencyReported schedules: 2.4mg each weekly.

Overview

A blend of an amylin analog and a GLP-1 receptor agonist. See the Stacks page and each component's page.

Looking for research material? Simple Research Peptides lists Cagrilintide + Semaglutide 5mg + 5mg Blend for laboratory research use.

Mechanism

This blend combines its components, each acting through its own pathway. See the linked component pages for how each one works.

Research areas

Storage & reconstitution

Supplied as a freeze-dried (lyophilized) powder in a sealed vial. Unopened vials are generally kept cold and away from light. Labs usually reconstitute it with bacteriostatic or sterile water, letting the liquid run down the vial wall and swirling gently instead of shaking. The solution is then kept refrigerated.

Recommended starting dose (low and slow)

Starting doseLow end of the studied range: 500 mcg; 2.4 mg.
FrequencyReported schedules: 2.4mg each weekly.
ReconstitutionExamples: 5 mg vial + 2 mL water = 2.5 mg/mL; 10mg blend vial + per blend diluent (as listed).

Studied higher doses

Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.

Highest amount reported in studiesTop of the studied range: 2.4 mg; 2.4 mg. These are range tops, not verified ceilings.

Route and timing

Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP

Cycle length and repeat

Pending - to be added by SRP

Half-life

Approximate, for Bobby's review: Both components last about a week.

Side effects

Pending - to be added by SRP

Suggested bloodwork and monitoring

Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; fasting glucose, HbA1c and lipid panel; lipase where GLP-1 or amylin-pathway compounds are involved.

Cautions

Pending - to be added by SRP

Reconstitution calculator

Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.

Frequently asked questions

What is Cagrilintide + Semaglutide Blend studied for?

In research it is studied for amylin + GLP-1 co-signaling. This blend combines its components, each acting through its own pathway.

How is Cagrilintide + Semaglutide Blend given in research?

Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.

What amount should a researcher start with?

This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.

Related peptides

Last updated: October 19, 2026

⚠ For research use only. Not for human use. Not medical advice.